Andrea Lobo,  —

Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.

Articles by Andrea Lobo

AAE linked to SLE, lupus nephritis in woman, 22: Case report

A 22-year-old woman with systemic lupus erythematosus (SLE), the most common form of lupus, developed acquired angioedema (AAE), a recent case report notes. “AAE may happen in adolescents and young adults. It could be an early manifestation of SLE,” the researchers wrote, adding that “practitioners must be aware…

Nearly half of HAE patients in UK on preventive treatment: Survey

Nearly half of hereditary angioedema (HAE) patients in the U.K. are on long-term prophylactic treatment to prevent swelling attacks, with more than 80% keeping a supply of on-demand therapies at home to treat sudden flares. That’s according to data from a new national survey that also provided information on…

Man develops angioedema after taking losartan for hypertension

A 48-year-old man developed angioedema after taking losartan, a medication commonly used to treat high blood pressure, a U.S. case study reported. Losartan, sold under the brand name Cozaar, is used to manage cardiovascular conditions, including lowering the risk of stroke with heart disease. To date, 20 reports have…

Poorly controlled HAE carries heavy burden, affecting life quality

A substantial proportion of adults with hereditary angioedema (HAE) in the Netherlands have poorly controlled disease, significantly affecting their quality of life, a survey study reported. Findings also linked well-controlled HAE to lower medical costs and greater productivity, relative to patients without adequate disease control. “Additional [preventive treatment] strategies…

Diagnosing and treating HAE most challenging across rural US

Diagnosing and treating hereditary angioedema (HAE) can be challenging, but it is particularly difficult when patients live in rural areas of the U.S., a study based on a survey of allergy and immunology specialists reported. “Misdiagnosis of symptoms, access to a specialist, and affording medications remain…

Canadian agency recommends cost of Orladeyo be covered

The Canadian Agency for Drugs and Technologies in Health (CADTH) has recommended Orladeyo (berotralstat) be reimbursed by public drug plans when used for the routine prevention of hereditary angioedema (HAE) attacks in patients 12 years and older. “We are still in need of additional options to help people…

Elder woman found to have acquired angiodema after tongue swelling

A 61-year-old woman in the U.S. was diagnosed with acquired angioedema and an underlying lymphoproliferative disorder after she sought treatment in an emergency department for sudden tongue swelling and difficulties in talking and swallowing, according to a case study. Lymphoproliferative disorders are characterized by the uncontrolled production of lymphocytes,…